Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.44 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23700382 | 0.94 | NMUR2 (0.49) | NMUR2NMUR1OPRM1OPRD1NPFFR1 | |
| SCHEMBL23710085 | 0.94 | NMUR2 (0.49) | NMUR2NMUR1OPRM1OPRD1NPFFR1 | |
| SCHEMBL23700385 | 0.94 | NMUR2 (0.49) | NMUR2NMUR1OPRM1OPRD1NPFFR1 | |
| SCHEMBL23700379 | 0.94 | NMUR2 (0.49) | NMUR2NMUR1OPRM1OPRD1NPFFR1 | |
| SCHEMBL23710102 | 0.89 | EPHA2 (0.49) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL23700186 | 0.86 | ABCB11 (0.50) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL23700187 | 0.86 | ABCB11 (0.50) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL23700189 | 0.86 | ABCB11 (0.50) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL23710105 | 0.86 | NMUR2 (0.49) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL23710062 | 0.84 | OPRM1 (0.45) | NMUR2NMUR1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238225-A1 | PEPTIDOMIMETIC INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238225-A1 | PEPTIDOMIMETIC INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) | PIN1, PPIA, PPIE | NMUR2 4347/4885NMUR1 4239/4885OPRM1 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.